Loading
4dmedical Limited Stock: price and insider trades · Australia
No insider purchase over the last 90 days. The latest was filed 22 Jun 2026.
4dmedical Limited: what insiders have been doing
4dmedical Limited, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to ASX. In the past year (17 October 2025 to 17 October 2026), 15 filings came from 8 insiders.
The flow runs one way only: 1 insider bought (1 purchase totalling €61k) and nobody sold on the market. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €61k, bought by Julian Bernard Kingsley Sutton and made public on 22 June 2026 (0.0046% of market cap). Those buying include 1 senior executive.
The last insider purchase was made public on 22 June 2026, 117 days ago. Filings reach the ASX feed a median of 2 days after the trade. This delay matters because a trade only becomes useful information once it is public.
Across the 2,222 companies tracked on its exchange, the median is 3 filings; at 15 filings, this issuer sits above that mark. The full history, which starts in 2026, counts 1 purchase against no sales.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from ASX disclosures alone and does not predict where the share price will go.
Insider Decl.
15
Thresholds
n/a
Buy Volume
€61,196
1 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJulian Bernard Kingsley Sutton1 buy
Since the insiders bought
- -14.4%Entry A$4.78 · Close 16 Oct 2026 A$4.09
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,723 of 24,148 companies
38.8
score / 100
Value30
Quality48
FCF yld-1.4%
Earn yld-1.2%
EV/EBITDA·
ROE-174%
Gross mgn92%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
A$4.25
Analyst consensus
3 analysts3.00/5
A$3.00Target A$4.37(+3%)A$6.00
Income statement
RevenueA$5.8M
Gross profitA$5.3M92% margin
EBITDA-A$24.8M-430% margin
Net income-A$30.1M-520.4% margin
Valuation
PER (forward)-217.9x
P/Book14.9x
Beta1.95
Balance sheet & cash
Market capA$2.6B
Total debtA$4.3M
Free Cash Flow-A$34.8M
Debt / Equity106%
Profitability & ownership
ROE-174.4%
ROA-15.6%
% insiders16.6%
% institutions23.8%
Last declaration on 24 September 2026
Declarations15 total
ShareASXISIN AU0000095416ASX:2924-03139628-3A702515
ShareASXISIN AU0000095416ASX:2924-03138930-3A702400
ShareASXISIN AU0000095416ASX:2924-03138414-3A702287
ShareASXISIN AU0000095416ASX:2924-03112521-3A697389
ShareASXISIN AU0000095416ASX:2924-03108290-3A696704
ShareASXISIN AU0000095416ASX:2924-03103118-3A695827
1 shares@ A$3.830.0046% mcap100.0% of flowShareASXISIN AU0000095416ASX:2924-03102842-3A695788
Canonical exit: 20 Sept 2026 (T+90)
ShareASXISIN AU0000095416ASX:2924-03102682-3A695762
ShareASXISIN AU0000095416ASX:2924-03102192-3A695672
ShareASXISIN AU0000095416ASX:2924-03094860-3A694234
15 of 15 declarations
About 4dmedical Limited
4dmedical Limited is a company focused on developing innovative solutions for the healthcare sector, emphasizing patient care improvement. It is listed on the XASX.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
